Literature DB >> 25342981

Targeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatment.

Haiying Cheng1, Marina Shcherba1, Gopichand Pendurti1, Yuanxin Liang1, Bilal Piperdi1, Roman Perez-Soler1.   

Abstract

The PI3K/AKT/mTOR pathway is commonly activated in non-small-cell lung cancer. It plays important roles in promoting oncogenesis in lung cancer and mediating resistance to EGF receptor tyrosine kinase inhibitors. Targeted agents against the components of this pathway are currently in development and their clinical benefits remain to be defined. This review provides an overview of the pathway dysregulation and novel agents targeting the pathway in lung cancer. In addition, potential predictive biomarkers guiding patient selection for targeted PI3K/AKT/mTOR inhibition is also discussed.

Entities:  

Year:  2014        PMID： 25342981      PMCID： PMC4203662          DOI： 10.2217/lmt.13.72

Source DB:  PubMed          Journal:  Lung Cancer Manag        ISSN： 1758-1966


  50 in total

Review 1.  Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer.

Authors:  Vassiliki Papadimitrakopoulou
Journal:  J Thorac Oncol       Date:  2012-08       Impact factor: 15.609

2.  Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis.

Authors:  Jian-Min Tang; Quan-Ying He; Rui-Xia Guo; Xiu-Jun Chang
Journal:  Lung Cancer       Date:  2006-02       Impact factor: 5.705

3.  Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer.

Authors:  Katharine A Price; Christopher G Azzoli; Lee M Krug; Maria C Pietanza; Naiyer A Rizvi; William Pao; Mark G Kris; Gregory J Riely; Robert T Heelan; Maria E Arcila; Vincent A Miller
Journal:  J Thorac Oncol       Date:  2010-10       Impact factor: 15.609

4.  The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.

Authors:  Iwan Beuvink; Anne Boulay; Stefano Fumagalli; Frederic Zilbermann; Stephan Ruetz; Terence O'Reilly; Francois Natt; Jonathan Hall; Heidi A Lane; George Thomas
Journal:  Cell       Date:  2005-03-25       Impact factor: 41.582

5.  Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.

Authors:  Jamie E Chaft; Maria E Arcila; Paul K Paik; Christopher Lau; Gregory J Riely; M Catherine Pietanza; Maureen F Zakowski; Valerie Rusch; Camelia S Sima; Marc Ladanyi; Mark G Kris
Journal:  Mol Cancer Ther       Date:  2011-12-01       Impact factor: 6.261

6.  Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors.

Authors:  Elizabeth Buck; Alexandra Eyzaguirre; Eric Brown; Filippo Petti; Siobhan McCormack; John D Haley; Kenneth K Iwata; Neil W Gibson; Graeme Griffin
Journal:  Mol Cancer Ther       Date:  2006-11       Impact factor: 6.261

Review 7.  PI3K and mTOR signaling pathways in cancer: new data on targeted therapies.

Authors:  Lise Willems; Jerome Tamburini; Nicolas Chapuis; Catherine Lacombe; Patrick Mayeux; Didier Bouscary
Journal:  Curr Oncol Rep       Date:  2012-04       Impact factor: 5.075

8.  Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability.

Authors:  Qi Xue; Benjamin Hopkins; Carole Perruzzi; Durga Udayakumar; David Sherris; Laura E Benjamin
Journal:  Cancer Res       Date:  2008-11-15       Impact factor: 12.701

9.  Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.

Authors:  Ker Yu; Lourdes Toral-Barza; Celine Shi; Wei-Guo Zhang; Judy Lucas; Boris Shor; Jamie Kim; Jeroen Verheijen; Kevin Curran; David J Malwitz; Derek C Cole; John Ellingboe; Semiramis Ayral-Kaloustian; Tarek S Mansour; James J Gibbons; Robert T Abraham; Pawel Nowak; Arie Zask
Journal:  Cancer Res       Date:  2009-07-07       Impact factor: 12.701

10.  Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors.

Authors:  J-C Soria; F A Shepherd; J-Y Douillard; J Wolf; G Giaccone; L Crino; F Cappuzzo; S Sharma; S H Gross; S Dimitrijevic; L Di Scala; H Gardner; L Nogova; V Papadimitrakopoulou
Journal:  Ann Oncol       Date:  2009-06-23       Impact factor: 32.976
View more
  42 in total

1.  Targeted Quantitative Proteomics Revealed Arsenite-induced Proteasomal Degradation of RhoB in Fibroblast Cells.

Authors:  Lok Ming Tam; Ming Huang; Yinsheng Wang
Journal:  Chem Res Toxicol       Date:  2019-06-10       Impact factor: 3.739

2.  RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors.

Authors:  Haiying Cheng; Yiyu Zou; Jeffrey S Ross; Kai Wang; Xuewen Liu; Balazs Halmos; Siraj M Ali; Huijie Liu; Amit Verma; Cristina Montagna; Abraham Chachoua; Sanjay Goel; Edward L Schwartz; Changcheng Zhu; Jidong Shan; Yiting Yu; Kira Gritsman; Roman Yelensky; Doron Lipson; Geoff Otto; Matthew Hawryluk; Philip J Stephens; Vincent A Miller; Bilal Piperdi; Roman Perez-Soler
Journal:  Cancer Discov       Date:  2015-09-14       Impact factor: 39.397

3.  Identification of subsets of actionable genetic alterations in KRAS-mutant lung cancers using association rule mining.

Authors:  Junior Tayou
Journal:  Cell Oncol (Dordr)       Date:  2018-04-20       Impact factor: 6.730

Review 4.  Targeting the Mammalian Target of Rapamycin in Lung Cancer.

Authors:  Glenn W Vicary; Jesse Roman
Journal:  Am J Med Sci       Date:  2016-08-21       Impact factor: 2.378

5.  CCR9-CCL25 interaction suppresses apoptosis of lung cancer cells by activating the PI3K/Akt pathway.

Authors:  Baijun Li; Zhiwei Wang; Yonglong Zhong; Jiao Lan; Xiangwei Li; Hui Lin
Journal:  Med Oncol       Date:  2015-02-18       Impact factor: 3.064

6.  A bibenzyl from Dendrobium ellipsophyllum induces apoptosis in human lung cancer cells.

Authors:  Anirut Hlosrichok; Somruethai Sumkhemthong; Boonchoo Sritularak; Pithi Chanvorachote; Chatchai Chaotham
Journal:  J Nat Med       Date:  2018-02-27       Impact factor: 2.343

7.  MicroRNA-133a downregulated EGFR expression in human non-small cell lung cancer cells via AKT/ERK signaling.

Authors:  Nannan Guo; Yingnan Zhao; Wen Zhang; Shaojun Li; Shanshan Li; Jianqi Yu
Journal:  Oncol Lett       Date:  2018-09-05       Impact factor: 2.967

8.  PRR14 is a novel activator of the PI3K pathway promoting lung carcinogenesis.

Authors:  M Yang; M Lewinska; X Fan; J Zhu; Z-M Yuan
Journal:  Oncogene       Date:  2016-04-04       Impact factor: 9.867

9.  Comprehensive micro-scaled proteome and phosphoproteome characterization of archived retrospective cancer repositories.

Authors:  Corinna Friedrich; Simon Schallenberg; Marieluise Kirchner; Matthias Ziehm; Sylvia Niquet; Mohamed Haji; Christin Beier; Jens Neudecker; Frederick Klauschen; Philipp Mertins
Journal:  Nat Commun       Date:  2021-06-11       Impact factor: 14.919

10.  Jorunnamycin A Suppresses Stem-Like Phenotypes and Sensitizes Cisplatin-Induced Apoptosis in Cancer Stem-Like Cell-Enriched Spheroids of Human Lung Cancer Cells.

Authors:  Somruethai Sumkhemthong; Supakarn Chamni; Gea U Ecoy; Pornchanok Taweecheep; Khanit Suwanborirux; Eakachai Prompetchara; Pithi Chanvorachote; Chatchai Chaotham
Journal:  Mar Drugs       Date:  2021-05-03       Impact factor: 5.118
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.